Alesi Surgical Secures £7m to Tackle Hazardous Surgical Smoke in Operating Theatres, Led by IW Capital

Key Takeaways

• Alesi raised £7 million (~$9 million) for global expansion
• Ultravision2 removes smoke up to 225× faster than competitors
• Regulatory mandates in 20 US states push smoke‑free operating rooms
• System cuts CO₂ usage by up to 82 % in laparoscopic surgery
• Over 50,000 keyhole procedures already used Alesi’s technology

Pulse Analysis

Surgical smoke is generated in roughly 90 percent of procedures, translating to an estimated 266 million operations annually worldwide. The aerosol contains particulates, chemicals and, in a small fraction, viable pathogens, creating both short‑term infection hazards and long‑term toxicity concerns for surgeons, nurses, and patients. Growing awareness of these risks has spurred legislative action, most notably in the United States where 20 states now require smoke‑free operating rooms, and Europe is tightening CE‑mark standards. This regulatory momentum is reshaping procurement priorities, making effective smoke‑control a prerequisite for modern operating suites.

Alesi Surgical’s Ultravision2 platform tackles the problem at its source through electrostatic precipitation, a method that captures smoke particles as they form rather than relying on bulky suction devices. Independent studies show the system clears the surgical field up to 225 times faster than traditional filtration, preserving visual clarity and enabling surgeons to operate at lower intra‑abdominal pressures. The technology also reduces CO₂ consumption by up to 82 percent, shortening procedure times and lowering overall costs. By integrating its own dissection tools, Ultravision2 offers a seamless workflow that addresses long‑standing adoption barriers such as equipment size, noise, and operational disruption.

The £7 million financing round, led by IW Capital with backing from IP Group and Mercia Ventures, provides Alesi the capital to accelerate international commercialization and develop the next‑generation Ultravision2 system for open surgeries. With over 50,000 keyhole procedures already completed using the first‑generation platform, the company is poised to capitalize on a market projected to exceed $2 billion as hospitals worldwide upgrade to compliant smoke‑management solutions. Investors see Alesi as a rare med‑tech play that combines strong clinical evidence, regulatory clearance, and a clear path to scaling across both minimally invasive and traditional surgical settings.